NCT01526616

Spironolactone Plus Metformin in Polycystic Ovary Syndrome

Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: University Magna Graecia · Academic / Other
• Sex: Female
• Age: 16 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.

Detailed description

In the present prospective, randomized study, we evaluated the efficacy of a combined therapy with metformin and low-dose spironolactone as compared to metformin alone on the clinical and endocrine-metabolic alterations of PCOS patients.

Conditions

• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Metformin	Metformin 850 mg twice a day for six months
DRUG	Metformin plus Spironolactone	Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-05-01
• Completion: 2011-07-01
• First posted: 2012-02-06
• Last updated: 2012-02-06